Paper40124344
Treatment of lung diseases via nanoparticles and nanorobots: Are these viable alternatives to overcome current treatments?
George M and 3 others. Mater Today Bio, 2025. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Treatment of lung diseases via nanoparticles and nanorobots: Are these viable alternatives to overcome current treatments? Papers, record 40124344. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40124344
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Treatment of lung diseases via nanoparticles and nanorobots: Are these viable alternatives to overcome current treatments?
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References329
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31815423 | Molecular Nanomachines Disrupt Bacterial Cell Wall, Increasing Sensitivity of Extensively Drug-Resistant Klebsiella pneumoniae to Meropenem. | ACS Nano | 2019 | https://conductscience.org/library/papers/31815423 | PubMed |
| 2 | 36549558 | Neutrophil membrane-coated nanoparticles exhibit increased antimicrobial activities in an anti-microbial resistant K. pneumonia infection model. | Nanomedicine | 2023 | https://conductscience.org/library/papers/36549558 | PubMed |
| 3 | 33666790 | Therapeutic efficacy of chitosan nanoparticles loaded with BCG-polysaccharide nucleic acid and ovalbumin on airway inflammation in asthmatic mice. | Eur J Clin Microbiol Infect Dis | 2021 | https://conductscience.org/library/papers/33666790 | PubMed |
| 4 | 37652327 | CD44 tagged hyaluronic acid - chitosan liposome carrier for the delivery of berberine and doxorubicin into lung cancer cells. | Int J Biol Macromol | 2023 | https://conductscience.org/library/papers/37652327 | PubMed |
| 5 | 27346486 | Hybrid-Actuating Macrophage-Based Microrobots for Active Cancer Therapy. | Sci Rep | 2016 | https://conductscience.org/library/papers/27346486 | PubMed |
| 6 | 21467058 | Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. | Chest | 2011 | https://conductscience.org/library/papers/21467058 | PubMed |
| 7 | 34474094 | Mesoporous silica nanoparticles for pulmonary drug delivery. | Adv Drug Deliv Rev | 2021 | https://conductscience.org/library/papers/34474094 | PubMed |
| 8 | 32832367 | High-Yield Production of Biohybrid Microalgae for On-Demand Cargo Delivery. | Adv Sci (Weinh) | 2020 | https://conductscience.org/library/papers/32832367 | PubMed |
| 9 | 33838013 | An Antibacterial Nanorobotic Approach for the Specific Targeting and Removal of Multiple Drug-Resistant Staphylococcus aureus. | Small | 2021 | https://conductscience.org/library/papers/33838013 | PubMed |
| 10 | 33636597 | Integrin αvβ3-targeted liposomal drug delivery system for enhanced lung cancer therapy. | Colloids Surf B Biointerfaces | 2021 | https://conductscience.org/library/papers/33636597 | PubMed |
| 11 | 37494584 | Microrobots for Biomedicine: Unsolved Challenges and Opportunities for Translation. | ACS Nano | 2023 | https://conductscience.org/library/papers/37494584 | PubMed |
| 12 | 35857516 | Magnetically steerable bacterial microrobots moving in 3D biological matrices for stimuli-responsive cargo delivery. | Sci Adv | 2022 | https://conductscience.org/library/papers/35857516 | PubMed |
| 13 | 35393247 | Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed. | Clin Lung Cancer | 2022 | https://conductscience.org/library/papers/35393247 | PubMed |
| 14 | 33341460 | Nanotechnology in pulmonary medicine. | Curr Opin Pharmacol | 2021 | https://conductscience.org/library/papers/33341460 | PubMed |
| 15 | 35112802 | Nano-in-Microparticles for Aerosol Delivery of Antibiotic-Loaded, Fucose-Derivatized, and Macrophage-Targeted Liposomes to Combat Mycobacterial Infections: In Vitro Deposition, Pulmonary Barrier Interactions, and Targeted Delivery. | Adv Healthc Mater | 2022 | https://conductscience.org/library/papers/35112802 | PubMed |
| 16 | 38626916 | Superparamagnetic Iron Oxide Nanoparticles Reprogram the Tumor Microenvironment and Reduce Lung Cancer Regrowth after Crizotinib Treatment. | ACS Nano | 2024 | https://conductscience.org/library/papers/38626916 | PubMed |
| 17 | 36678633 | Inhalable Polymeric Nanoparticles for Pulmonary Delivery of Antimicrobial Peptide SET-M33: Antibacterial Activity and Toxicity In Vitro and In Vivo. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36678633 | PubMed |
| 18 | 33277608 | Engineering precision nanoparticles for drug delivery. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/33277608 | PubMed |
| 19 | 31660180 | Errors in inhaler use related to devices and to inhalation technique among patients with chronic obstructive pulmonary disease in primary health care. | Nurs Open | 2019 | https://conductscience.org/library/papers/31660180 | PubMed |
| 20 | 24836950 | X-ray CT and pneumonia inhibition properties of gold-silver nanoparticles for targeting MRSA induced pneumonia. | Biomaterials | 2014 | https://conductscience.org/library/papers/24836950 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42194071 | Biomolecular Interfaces in Targeted Nano-Drug Delivery: Molecular Recognition, Signaling Modulation, and Translational Pathways. | Biomolecules | 2026 | https://conductscience.org/library/papers/42194071 | PubMed |
| 41424454 | Nasal Delivery of Phytochemicals Using Nanocarriers: Therapeutic Opportunities and Translational Challenges. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/41424454 | PubMed |
| 41003423 | Bio-Functional Nanomaterials for Enhanced Lung Cancer Therapy: The Synergistic Roles of Vitamins D and K. | J Funct Biomater | 2025 | https://conductscience.org/library/papers/41003423 | PubMed |
| 40733101 | Inhalable Nanotechnology-Based Drug Delivery Systems for the Treatment of Inflammatory Lung Diseases. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40733101 | PubMed |
| 40471989 | Assessing the biomedical applicability of biogenically synthesized AuNPs using Salvia splendens extract. | PLoS One | 2025 | https://conductscience.org/library/papers/40471989 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40124344
GET https://conductscience.org/api/papers/v1/40124344/references?page=2